CSPC reports revenue drop in challenging first half

In the first half of 2025, CSPC Pharmaceutical Group reported revenue of 13,273m yuan, an 18.5% decrease from 16,284m yuan in the same period last year. Profit attributable to shareholders also fell by 15.6% to 2,548m yuan. This decline was primarily attributed to two key products being included in centralized volume-based procurement, leading to substantial price reductions.

Despite these challenges, the group's bulk product business saw an 11.9% increase in sales revenue to 2,075m yuan, driven by a 21.6% rise in Vitamin C product sales to 1,196m yuan due to increased overseas demand. Licence fee income, a new growth driver, reached 1,075m yuan. Research and development expenses increased by 5.5% to 2,683m yuan.

CSPC maintained a solid financial position with bank deposits, balances, and cash totaling 10,291m yuan as of June 30, 2025, up from 9,187m yuan at the end of 2024. The group actively repurchased 64.3m shares for HK$300m to enhance shareholder returns. An interim dividend of HK14 cents per share was declared for 2025.